Clinical Trials

Test tubes and microscope

Since 1999, Vitreo-Retinal Associates has conducted more than 50 clinical research trials in an effort to provide our patients with cutting edge treatments for retinal diseases. These programs allow our patients access to the most up-to-date treatments and medications not yet available to the general public. VRA’s physicians and full time research staff are proud to be the area’s leader in innovative eye research.

Did you know that VRA played a role in the discovery of drugs used to treat wet macular degeneration? Every week we perform hundreds of injections of Avastin, Lucentis, and Eylea for macular degeneration, but there was a time when these drugs did not exist! With the help of our patient volunteers, VRA has participated in several of the studies which are required by the FDA in order to gain approval for medications like Lucentis and Eylea!

New studies with cutting-edge treatments for our patients’ retinal diseases are always on the horizon!

Current Clinical Research Trials

  • Investigator Initiated Protocol SM09-0626-01  Lipid and Cytokine Analysis of Vitreous Samples from Clinically Indicated Vitrectomies
  • Genentech-Roche Ltd GR40398 RHINE Study of RO6867461 in patients with Diabetic Macular Edema
  • DRCR Protocol AC:  Aflibercept vs. Bevacizumab + Deferred Aflibercept for the treatment of Diabetic Macular Edema
  • Chengdu Kanghong Panda 2:  Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-Related Macular Degeneration
  • Genentech, Inc GR40973 GAllego study of R07171009 in patients with Geographic Atrophy secondary to Age-Related Macular Degeneration
  • Novartis Pharmaceuticals:  Study of Efficacy ansd Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
  • RHONE-X:  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Rhone-X)
  • SCD411-CP101:  A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity Between SCD411 and Eylea®  in Subjects With Neovascular Age-related Macular Degeneration

Past Clinical Research Trials

To Learn More About Our Clinical Research Trials, Please Contact:

Carla Smith, Clinical Research Coordinator

Vitreo-Retinal Associates
2505 E Paris Ave, SE
Suite 100
Grand Rapids, MI 49546


Grand Rapids: 616.285.1200
Kalamazoo: 269.353.9700
Muskegon: 231.830.1200
Ionia: 616.285.1200